Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.02
TEVA's Cash-to-Debt is ranked lower than
96% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. TEVA: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.23 Max: 1.03
Current: 0.02
0.02
1.03
Equity-to-Asset 0.32
TEVA's Equity-to-Asset is ranked lower than
83% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TEVA: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.49 Max: 0.6
Current: 0.32
0.32
0.6
Debt-to-Equity 1.25
TEVA's Debt-to-Equity is ranked lower than
85% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. TEVA: 1.25 )
Ranked among companies with meaningful Debt-to-Equity only.
TEVA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27  Med: 0.57 Max: 1.25
Current: 1.25
0.27
1.25
Piotroski F-Score: 3
Altman Z-Score: 0.38
Beneish M-Score: -2.65
WACC vs ROIC
3.33%
-7.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -18.04
TEVA's Operating Margin % is ranked higher than
51% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. TEVA: -18.04 )
Ranked among companies with meaningful Operating Margin % only.
TEVA' s Operating Margin % Range Over the Past 10 Years
Min: -18.04  Med: 17.02 Max: 25.46
Current: -18.04
-18.04
25.46
Net Margin % -25.19
TEVA's Net Margin % is ranked lower than
67% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. TEVA: -25.19 )
Ranked among companies with meaningful Net Margin % only.
TEVA' s Net Margin % Range Over the Past 10 Years
Min: -25.19  Med: 12.03 Max: 20.75
Current: -25.19
-25.19
20.75
ROE % -19.13
TEVA's ROE % is ranked lower than
69% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. TEVA: -19.13 )
Ranked among companies with meaningful ROE % only.
TEVA' s ROE % Range Over the Past 10 Years
Min: -19.13  Med: 10 Max: 16.18
Current: -19.13
-19.13
16.18
ROA % -6.89
TEVA's ROA % is ranked lower than
66% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. TEVA: -6.89 )
Ranked among companies with meaningful ROA % only.
TEVA' s ROA % Range Over the Past 10 Years
Min: -6.89  Med: 4.98 Max: 9.34
Current: -6.89
-6.89
9.34
ROC (Joel Greenblatt) % -62.05
TEVA's ROC (Joel Greenblatt) % is ranked higher than
51% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. TEVA: -62.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -62.05  Med: 33.66 Max: 49.49
Current: -62.05
-62.05
49.49
3-Year Revenue Growth Rate -1.60
TEVA's 3-Year Revenue Growth Rate is ranked lower than
73% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TEVA: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 14.9 Max: 37.4
Current: -1.6
-1.6
37.4
3-Year EBITDA Growth Rate -8.00
TEVA's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. TEVA: -8.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.6  Med: 16.3 Max: 47.4
Current: -8
-9.6
47.4
3-Year EPS without NRI Growth Rate -63.90
TEVA's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. TEVA: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 16 Max: 119.7
Current: -63.9
-63.9
119.7
GuruFocus has detected 4 Warning Signs with Teva Pharmaceutical Industries Ltd $TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEVA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TEVA Guru Trades in Q3 2016

Paul Tudor Jones 5,930 sh (New)
NWQ Managers 2,663,631 sh (+58.75%)
Jim Simons 1,947,963 sh (+40.37%)
Jeremy Grantham 336,700 sh (+17.19%)
Barrow, Hanley, Mewhinney & Strauss 26,570,988 sh (+17.05%)
Michael Price 469,300 sh (+6.59%)
Vanguard Health Care Fund 6,746,400 sh (+6.13%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 542,000 sh (unchged)
John Griffin Sold Out
Ronald Muhlenkamp 175,770 sh (-0.50%)
Keeley Asset Management Corp 56,869 sh (-2.23%)
Manning & Napier Advisors, Inc 113,436 sh (-2.46%)
David Dreman 31,969 sh (-3.92%)
John Paulson 16,076,900 sh (-4.15%)
Richard Snow 965,986 sh (-10.23%)
Andreas Halvorsen 19,684,219 sh (-29.03%)
Larry Robbins 2,176,144 sh (-29.41%)
Signature Select Canadian Fund 40,500 sh (-58.38%)
» More
Q4 2016

TEVA Guru Trades in Q4 2016

Julian Robertson 554,800 sh (New)
David Tepper 5,053,000 sh (New)
Michael Price 696,500 sh (+48.41%)
Ronald Muhlenkamp 239,889 sh (+36.48%)
Vanguard Health Care Fund 8,922,300 sh (+32.25%)
Barrow, Hanley, Mewhinney & Strauss 32,455,432 sh (+22.15%)
Jim Simons 2,165,863 sh (+11.19%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Larry Robbins Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
John Paulson 15,925,800 sh (-0.94%)
Manning & Napier Advisors, Inc 84,033 sh (-25.92%)
David Dreman 16,751 sh (-47.60%)
NWQ Managers 858,877 sh (-67.76%)
Keeley Asset Management Corp 16,603 sh (-70.80%)
Richard Snow 191,703 sh (-80.15%)
Jeremy Grantham 14,950 sh (-95.56%)
Eaton Vance Worldwide Health Sciences Fund 416,622 sh (-23.13%)
» More
Q1 2017

TEVA Guru Trades in Q1 2017

Francis Chou 215,000 sh (New)
Caxton Associates 12,200 sh (New)
Jim Simons 4,817,763 sh (+122.44%)
Vanguard Health Care Fund 11,717,600 sh (+31.33%)
Manning & Napier Advisors, Inc 96,678 sh (+15.05%)
NWQ Managers 926,179 sh (+7.84%)
Michael Price 720,000 sh (+3.37%)
Julian Robertson 557,600 sh (+0.50%)
George Soros 600,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Steven Cohen 50,000 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Jeremy Grantham Sold Out
Signature Select Canadian Fund Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
David Dreman 15,646 sh (-6.60%)
Barrow, Hanley, Mewhinney & Strauss 29,753,982 sh (-8.32%)
John Paulson 10,997,300 sh (-30.95%)
Ronald Muhlenkamp 106,645 sh (-55.54%)
David Tepper 2,175,000 sh (-56.96%)
Richard Snow 73,227 sh (-61.80%)
» More
Q2 2017

TEVA Guru Trades in Q2 2017

Bernard Horn 199,100 sh (+203.51%)
David Dreman 44,438 sh (+184.02%)
Francis Chou 505,000 sh (+134.88%)
Vanguard Health Care Fund 15,965,000 sh (+36.25%)
Julian Robertson 694,600 sh (+24.57%)
Ray Dalio 27,700 sh (+12.15%)
Caxton Associates 13,000 sh (+6.56%)
NWQ Managers 967,279 sh (+4.44%)
Barrow, Hanley, Mewhinney & Strauss 29,963,830 sh (+0.71%)
First Eagle Investment 200 sh (unchged)
Michael Price 720,000 sh (unchged)
George Soros 600,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Jim Simons Sold Out
David Tepper Sold Out
Ronald Muhlenkamp 106,505 sh (-0.13%)
Richard Snow 63,752 sh (-12.94%)
John Paulson 6,744,000 sh (-38.68%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 0.71%0.01%$27.82 - $32.95 $ 17.19-44%29,963,830
Vanguard Health Care Fund 2017-06-30 Add 36.25%0.3%$27.82 - $32.95 $ 17.19-44%15,965,000
John Paulson 2017-06-30 Reduce -38.68%1.83%$27.82 - $33.22 $ 17.19-44%6,744,000
NWQ Managers 2017-06-30 Add 4.44%0.02%$27.82 - $32.95 $ 17.19-44%967,279
Julian Robertson 2017-06-30 Add 24.57%0.9%$27.82 - $32.95 $ 17.19-44%694,600
Ronald Muhlenkamp 2017-06-30 Reduce -0.13%$27.82 - $32.95 $ 17.19-44%106,505
David Dreman 2017-06-30 Add 184.02%0.52%$27.82 - $33.22 $ 17.19-44%44,438
David Tepper 2017-06-30 Sold Out 1.15%$27.82 - $32.95 $ 17.19-44%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -8.32%0.15%$32.09 - $37.96 $ 17.19-50%29,753,982
Vanguard Health Care Fund 2017-03-31 Add 31.33%0.2%$32.09 - $37.96 $ 17.19-50%11,717,600
John Paulson 2017-03-31 Reduce -30.95%2.28%$32.09 - $37.96 $ 17.19-50%10,997,300
David Tepper 2017-03-31 Reduce -56.96%1.85%$32.09 - $37.96 $ 17.19-50%2,175,000
NWQ Managers 2017-03-31 Add 7.84%0.03%$32.09 - $37.96 $ 17.19-50%926,179
Michael Price 2017-03-31 Add 3.37%0.09%$32.09 - $37.96 $ 17.19-50%720,000
Julian Robertson 2017-03-31 Add 0.50%0.02%$32.09 - $37.96 $ 17.19-50%557,600
Ronald Muhlenkamp 2017-03-31 Reduce -55.54%1.53%$32.09 - $37.96 $ 17.19-50%106,645
David Dreman 2017-03-31 Reduce -6.60%0.02%$32.09 - $37.96 $ 17.19-50%15,646
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Add 22.15%0.32%$35.03 - $45.68 $ 17.19-57%32,455,432
John Paulson 2016-12-31 Reduce -0.94%0.08%$35.03 - $45.68 $ 17.19-57%15,925,800
Vanguard Health Care Fund 2016-12-31 Add 32.25%0.19%$35.03 - $45.68 $ 17.19-57%8,922,300
David Tepper 2016-12-31 New Buy3.25%$35.03 - $45.68 $ 17.19-57%5,053,000
NWQ Managers 2016-12-31 Reduce -67.76%1.21%$35.03 - $45.68 $ 17.19-57%858,877
Michael Price 2016-12-31 Add 48.41%1%$35.03 - $45.68 $ 17.19-57%696,500
Julian Robertson 2016-12-31 New Buy3.65%$35.03 - $45.68 $ 17.19-57%554,800
Ronald Muhlenkamp 2016-12-31 Add 36.48%0.74%$35.03 - $45.68 $ 17.19-57%239,889
David Dreman 2016-12-31 Reduce -47.60%0.42%$35.03 - $45.68 $ 17.19-57%16,751
Keeley Asset Management Corp 2016-12-31 Reduce -70.80%0.08%$35.03 - $45.68 $ 17.19-57%16,603
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Add 17.05%0.27%$46.01 - $55.45 $ 17.19-67%26,570,988
John Paulson 2016-09-30 Reduce -4.15%0.36%$46.01 - $55.45 $ 17.19-67%16,076,900
Vanguard Health Care Fund 2016-09-30 Add 6.13%0.04%$46.01 - $55.45 $ 17.19-67%6,746,400
NWQ Managers 2016-09-30 Add 58.75%0.66%$46.01 - $55.45 $ 17.19-67%2,663,631
Michael Price 2016-09-30 Add 6.59%0.18%$46.01 - $55.45 $ 17.19-67%469,300
Ronald Muhlenkamp 2016-09-30 Reduce -0.50%0.02%$46.01 - $55.45 $ 17.19-67%175,770
Keeley Asset Management Corp 2016-09-30 Reduce -2.23%$46.01 - $55.45 $ 17.19-67%56,869
David Dreman 2016-09-30 Reduce -3.92%0.04%$46.01 - $55.45 $ 17.19-67%31,969
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF338.0020.737 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:TARO, NAS:STDY, OTCPK:OWCP, ASX:ESE » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

TEVA PHARMACEUTICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - (TEVA)
Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 23rd Lead Plaintiff Deadline in Class Action Against Teva Pharmaceutical Industries Ltd. (TEVA)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Teva Pharmaceutical Industries Ltd. To Contact The Firm
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 – TEVA
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited (TEVA)
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm
IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm
Stocks Climb as S&P Hits Record High Indexes up in morning trading
U.S. stock market indexes opened higher on Tuesday. The Dow Jones Industrial Average rose 33.19 points to open at 22,090.56. The Standard & Poor’s 500 index opened up 0.2% at 2,491.94, an intraday record high. The Nasdaq 100 index rose 16.55 points to open at 6,448.81. The dollar index is up 0.18%. Read more...
Get a stock report on Alcoa, Ford, Health Insurance Innovations, Teva, Tesla Motors, or any stock you choose
The Cooper Companies Announces Definitive Agreement to Acquire PARAGARD® IUD From Teva

Ratios

vs
industry
vs
history
Forward PE Ratio 4.39
TEVA's Forward PE Ratio is ranked higher than
94% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. TEVA: 4.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.73
TEVA's PB Ratio is ranked higher than
86% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. TEVA: 0.73 )
Ranked among companies with meaningful PB Ratio only.
TEVA' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 2.08 Max: 2.91
Current: 0.73
0.65
2.91
PS Ratio 0.76
TEVA's PS Ratio is ranked higher than
75% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. TEVA: 0.76 )
Ranked among companies with meaningful PS Ratio only.
TEVA' s PS Ratio Range Over the Past 10 Years
Min: 0.67  Med: 2.57 Max: 4.33
Current: 0.76
0.67
4.33
Price-to-Free-Cash-Flow 5.49
TEVA's Price-to-Free-Cash-Flow is ranked higher than
87% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. TEVA: 5.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.94  Med: 13.41 Max: 32.03
Current: 5.49
4.94
32.03
Price-to-Operating-Cash-Flow 4.22
TEVA's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. TEVA: 4.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.8  Med: 10.49 Max: 22.47
Current: 4.22
3.8
22.47
EV-to-EBIT -11.55
TEVA's EV-to-EBIT is ranked lower than
89% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. TEVA: -11.55 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.7  Med: 20.6 Max: 192.9
Current: -11.55
-14.7
192.9
EV-to-EBITDA -19.03
TEVA's EV-to-EBITDA is ranked lower than
69% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. TEVA: -19.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.2  Med: 14.1 Max: 39.1
Current: -19.03
-24.2
39.1
EV-to-Revenue 2.49
TEVA's EV-to-Revenue is ranked higher than
51% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. TEVA: 2.49 )
Ranked among companies with meaningful EV-to-Revenue only.
TEVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.2 Max: 4.6
Current: 2.49
2.1
4.6
Shiller PE Ratio 10.36
TEVA's Shiller PE Ratio is ranked higher than
91% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. TEVA: 10.36 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.34  Med: 26.27 Max: 60.19
Current: 10.36
9.34
60.19
Current Ratio 0.94
TEVA's Current Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVA: 0.94 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.58 Max: 2.95
Current: 0.94
0.9
2.95
Quick Ratio 0.61
TEVA's Quick Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. TEVA: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.03 Max: 2.19
Current: 0.61
0.61
2.19
Days Inventory 154.07
TEVA's Days Inventory is ranked lower than
69% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. TEVA: 154.07 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 154.07  Med: 186.4 Max: 208.14
Current: 154.07
154.07
208.14
Days Sales Outstanding 114.32
TEVA's Days Sales Outstanding is ranked lower than
75% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. TEVA: 114.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 114.32
95.91
153.21
Days Payable 72.05
TEVA's Days Payable is ranked higher than
57% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. TEVA: 72.05 )
Ranked among companies with meaningful Days Payable only.
TEVA' s Days Payable Range Over the Past 10 Years
Min: 72.05  Med: 84.39 Max: 111.41
Current: 72.05
72.05
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 6.41
TEVA's Dividend Yield % is ranked higher than
94% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TEVA: 6.41 )
Ranked among companies with meaningful Dividend Yield % only.
TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.66  Med: 2.11 Max: 8.77
Current: 6.41
0.66
8.77
3-Year Dividend Growth Rate 2.00
TEVA's 3-Year Dividend Growth Rate is ranked lower than
63% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. TEVA: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 23.6 Max: 80.9
Current: 2
-6.7
80.9
Forward Dividend Yield % 6.44
TEVA's Forward Dividend Yield % is ranked higher than
93% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 6.44 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 9.86
TEVA's 5-Year Yield-on-Cost % is ranked higher than
92% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. TEVA: 9.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.02  Med: 3.25 Max: 13.49
Current: 9.86
1.02
13.49
3-Year Average Share Buyback Ratio -2.30
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 4.6
Current: -2.3
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.31
TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. TEVA: 0.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.31  Med: 1.57 Max: 11.3
Current: 0.31
0.31
11.3
Price-to-Median-PS-Value 0.29
TEVA's Price-to-Median-PS-Value is ranked higher than
90% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. TEVA: 0.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.07 Max: 2.26
Current: 0.29
0.28
2.26
Earnings Yield (Greenblatt) % -8.65
TEVA's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVA: -8.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9  Med: 4.75 Max: 8.8
Current: -8.65
-9
8.8
Forward Rate of Return (Yacktman) % 15.38
TEVA's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. TEVA: 15.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 22.7 Max: 45.5
Current: 15.38
-2
45.5

More Statistics

Revenue (TTM) (Mil) $23,371.00
EPS (TTM) $ -6.13
Beta0.62
Short Percentage of Float0.00%
52-Week Range $15.22 - 51.51
Shares Outstanding (Mil)1,016.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 22,689 21,905 22,494 22,692
EPS ($) 4.29 4.08 4.54 4.64
EPS without NRI ($) 4.29 4.08 4.54 4.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-2.92%
Dividends per Share ($) 0.60 0.36 0.41
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 23rd Lead Plaintiff Deadline in Clas Sep 21 2017 
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi Sep 20 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. Sep 20 2017 
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC R Sep 15 2017 
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pha Sep 13 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharm Sep 12 2017 
Get a stock report on Alcoa, Ford, Health Insurance Innovations, Teva, Tesla Motors, or any stock yo Sep 12 2017 
3 Stocks Climb as S&P Hits Record High Sep 12 2017 
The Cooper Companies Announces Definitive Agreement to Acquire PARAGARD® IUD From Teva Sep 11 2017 
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Teva Sep 11 2017 

More From Other Websites
TEVA PHARMACEUTICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF... Sep 22 2017
Generic Drug Makers Face Pricing Issues That Other Pharmas Don't Sep 22 2017
Teva Pharmaceutical Industries Ltd. : TEVA-US: Dividend Analysis : August 29th, 2017 (record date) :... Sep 21 2017
EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical... Sep 21 2017
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Teva... Sep 21 2017
Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 23rd Lead Plaintiff Deadline in... Sep 21 2017
[$$] Teva Pharmaceutical Stock Could Double Sep 21 2017
Our 5 Top Picks For A Booming Marijuana Market Sep 20 2017
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses... Sep 20 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva... Sep 20 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd.... Sep 20 2017
Teva/Nuvelution to Speed Up Development of Austedo in US Sep 20 2017
[$$] States Push Ahead With Investigation Into Opioid Painkillers Sep 19 2017
SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva... Sep 19 2017
State attorneys general subpoena opioid makers and dealer... Sep 19 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a... Sep 19 2017
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from... Sep 19 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Teva... Sep 19 2017
Teva shares rise on debt covenant amendments Sep 19 2017
Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets... Sep 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}